Lido Advisors LLC Buys 2,312 Shares of Cencora, Inc. (NYSE:COR)

Lido Advisors LLC raised its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 44.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,502 shares of the company's stock after acquiring an additional 2,312 shares during the quarter. Lido Advisors LLC's holdings in Cencora were worth $1,686,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in COR. Whittier Trust Co. increased its stake in Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after purchasing an additional 44 shares during the last quarter. Shepherd Financial Partners LLC grew its position in shares of Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after buying an additional 46 shares during the last quarter. WASHINGTON TRUST Co raised its stake in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares during the period. JFS Wealth Advisors LLC boosted its stake in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. grew its holdings in shares of Cencora by 1.1% during the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock valued at $1,003,000 after purchasing an additional 47 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

Cencora stock traded up $11.37 during mid-day trading on Wednesday, hitting $302.18. The company's stock had a trading volume of 987,248 shares, compared to its average volume of 1,683,067. The stock has a market capitalization of $58.60 billion, a P/E ratio of 42.95, a P/E/G ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $309.35. The stock's fifty day moving average price is $274.32 and its two-hundred day moving average price is $252.29. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same period in the previous year, the firm earned $3.80 earnings per share. Cencora's revenue for the quarter was up 10.3% compared to the same quarter last year. Research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on COR shares. UBS Group boosted their price objective on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Bank of America boosted their price objective on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Finally, Wells Fargo & Company increased their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $290.00.

Insider Activity at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. The trade was a 21.96 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,223 shares of company stock worth $13,580,967. 10.80% of the stock is owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.